EUVIMEDScopri EUVIMED
Open access · CC BY 4.0

Beyond the two‐trials rule

Leonhard Held iD

Statistics in Medicine · 2024

DOI: 10.1002/sim.10055 ↗

At a glance

Journal article in Statistics in Medicine, 2024. Written by Leonhard Held. Institution: Epidemiology, Biostatistics and Prevention Institute (EBPI) and Center for Reproducible Science (CRS), University of Zurich, Zurich, Switzerland. Major MEDLINE topics: Drug Approval. Cited 15 times so far (Crossref); 39 references. The full text is freely available (open access, CC BY 4.0). Funded by: Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung.

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

The two‐trials rule for drug approval requires “at least two adequate and well‐controlled studies, each convincing on its own, to establish effectiveness.” This is usually implemented by requiring two significant pivotal trials and is the standard regulatory requirement to provide evidence for a new drug's efficacy. However, there is need to develop suitable alternatives to this rule for a number of reasons, including the possible availability of data from more than two trials. I consider the case of up to three studies and stress the importance to control the partial Type‐I error rate, where only some studies have a true null effect, while maintaining the overall Type‐I error rate of the two‐trials rule, where all studies have a null effect. Some less‐known ‐value combination methods are useful to achieve this: Pearson's method, Edgington's method and the recently proposed harmonic mean ‐test. I study their properties and discuss how they can be extended to a sequential assessment of success while still ensuring overall Type‐I error control. I compare the different methods in terms of partial Type‐I error rate, project power and the expected number of studies required. Edgington's method is eventually recommended as it is easy to implement and communicate, has only moderate partial Type‐I error rate inflation but substantially increased project power.

Subjects

MeSH terms (MEDLINE)

Drug ApprovalHumansClinical Trials as TopicModels, StatisticalResearch Design

Author keywords

Edgington's methodType‐I error controlreplicabilitysequential methods

Authors and institutions

  • Epidemiology, Biostatistics and Prevention Institute (EBPI) and Center for Reproducible Science (CRS), University of Zurich, Zurich, Switzerland.

ORCID profiles: Leonhard Held

Funding

  • Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung

Cite

APA

Held, L. (2024). Beyond the two‐trials rule. Statistics in Medicine. https://doi.org/10.1002/sim.10055

Vancouver

Held L. Beyond the two‐trials rule. Statistics in Medicine. 2024. doi:10.1002/sim.10055

BibTeX
@article{Held2024,
  author = {Held, Leonhard},
  title = {Beyond the two‐trials rule},
  journal = {Statistics in Medicine},
  year = {2024},
  doi = {10.1002/sim.10055}
}
Start for free →